Although EGFR is mutated in a large fraction of NSCLC, and it acts as an established tumor driver, under pharmacological stress this driver seems to be replaced by an alliance comprising, in addition to EGFR, also HER2 and HER3. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.